CORDIS - Resultados de investigaciones de la UE
CORDIS

Heal Mastitis in Dairy Cattle

Periodic Reporting for period 1 - HealMastitis (Heal Mastitis in Dairy Cattle)

Período documentado: 2017-12-01 hasta 2018-05-31

Mastitis is considered to be one of the most widespread and common dairy cattle diseases and is characterized as an endemic disease affecting dairy herds worldwide. In herds without an effective mastitis control program, ca. 40% of cows are infected in an average of 6 months. Mastitis is the most costly disease that inflicts major economic losses to the dairy industry. Treatment of mastitis costs ca. €185 per cow per year. Antibiotic treatment is currently the only possible solution for treating mastitis caused by bacteria. Massive usage of antibiotics creates bacteria that are resistant to antibiotics, and antibiotic resistance is a worldwide problem. Use of antibiotics against mastitis increases the antibiotics residues that are present in milk consumed by consumer making it harmful for human health.

Our technology will be an important tool to keep the society safe and healthy by keeping the milk free from antibiotics. Consumers will feel safer and will lead a healthier life. It is also important to provide the dairy industry an innovative technology to prevent Mastitis in order to supply good quality milk to the people.

We have developed a technology to treat the mastitis disease in dairy cattle without any antibiotics. Our system communicates with the farm computer, receives the energetic signature of the mastitis pathogens of the cattle in the farm and processes the cows’ drinking water according to the information received from a microbiological laboratory. During this feasibility study, we would like to analyse the market and consolidate the business plan.
The following main activities have been performed during the six-month feasibility study:
• Revision of technical design of the system to reduce manufacturing cost
• Product supply chain identification
• Communication with major diary industry in Germany, the Netherlands, The UK, Ireland, France and Israel
• Market analysis that includes size, growth and trend of niche market for the PRISE. The market opportunity of our product and necessary strategies have been studied.
• Competitor analysis.
• Technical, environmental, management and commercial risks have been investigated.
• Strength, Weakness, Opportunities and Threats (SWOT) and Porter’s five forces analysis.
• Financial plan for next five years were done
• IPR management plan have been formulated
• Consolidated business plan.

The main results of our activities:
• The entire system was evaluated and it is optimized to reduce the cost by ca. 25%
• We communicated with several dairy industries in the Europe and could established preliminary contacts to validate our system during the planned phase 2 project.
• We have strengthen our supply chain.
• We have identified our niche market, its size, growth and trends.
• The potential risks of our product are identified and we have developed necessary measures to overcome the potential risks.
• We consulted with an IPR attorney to verify the chance of patent application of our system. The positive analysis will allow us to apply for the patent soon.
The project results allow us to understand out product’s opportunity in the niche market and guide us to prepare our strategies to penetrate the market within a very short time. With our new cost effective technical design and current market strategies, the next five years financial plan has been prepared. Finally, all surveys and analyses support to update our business plan. The project outcome will facilitate us to reach TRL 9 from TRL 6 very conveniently in future, during our planned Phase 2 project.
Heal Mastisis